Cortexin vs Retatrutide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Cortexin
Cortexin is a polypeptide complex derived from pig brain cortex, used clinically in Russia and Eastern Europe for neurological conditions including stroke recovery, traumatic brain injury, and cognitive decline.
Full details →Retatrutide
Retatrutide is an investigational triple agonist targeting GIP, GLP-1, and glucagon receptors. Phase 2 trials showed unprecedented weight loss of up to 24% at 48 weeks, making it potentially the most effective obesity treatment studied.
Full details →Side-by-Side Comparison
| Aspect | Cortexin | Retatrutide |
|---|---|---|
| Mechanism | Contains a mixture of neuropeptides and amino acids that support neuronal metabolism, provide neuroprotection, and enhance synaptic transmission. Specific mechanisms not fully characterized. | Triple receptor activation provides complementary metabolic effects: GLP-1 and GIP reduce appetite and improve insulin sensitivity, while glucagon receptor activation increases energy expenditure and promotes hepatic fat oxidation. |
| Typical Dosage | Clinical protocols: 10mg intramuscularly once daily for 10-20 days. May be repeated after 3-6 month interval. | Clinical trials used doses from 1mg to 12mg weekly. Optimal dosing still being determined in ongoing Phase 3 trials. |
| Administration | Intramuscular injection. Comes as lyophilized powder requiring reconstitution. Treatment given in courses rather than continuously. | Subcutaneous injection once weekly. Currently only available through clinical trials - not yet FDA approved. |
| Side Effects | Generally well-tolerated. May cause injection site reactions or mild allergic responses in sensitive individuals. | Similar GI effects to other incretin-based therapies: nausea, diarrhea, vomiting, constipation. Dose-dependent severity. |
| Best For |